Funaro A, Horenstein A L, Santoro P, Cinti C, Gregorini A, Malavasi F
Department of Genetics, Biology and Biochemistry, University of Turin, Turin, Italy.
Biotechnol Adv. 2000 Aug;18(5):385-401. doi: 10.1016/s0734-9750(00)00043-4.
This survey is an overview of the applications of murine, humanized and recombinant monoclonal antibodies for in vivo diagnostic and therapeutic applications. Monoclonal antibodies (mAb) have been applied to the diagnosis and therapy of an array of human diseases. The initial failures of early clinical trials have been overcome through the production of a new generation of mAb which features reduced immunogenicity and improved targeting abilities. The early models of mAb therapy were focused on enhancing the cytolytic mechanisms against the tumor cells. More recently, successful mAb-based therapies were targeted to molecules involved in the regulation of growth of cancer cells. This has highlighted the relevance of understanding receptor-mediated signaling events, and may provide new opportunities for anti-tumor antibody targeting. Despite all the difficulties, clinical data is outlining an increasingly significant role for antibody-mediated cancer therapy as a versatile and powerful instrument in cancer treatment. One reasonable expectation is that treatment at an earlier stage in the disease process or in minimal residual disease may be more advantageous.
本综述概述了鼠源、人源化和重组单克隆抗体在体内诊断和治疗应用中的情况。单克隆抗体（mAb）已应用于一系列人类疾病的诊断和治疗。早期临床试验的最初失败已通过新一代单克隆抗体的生产得以克服，新一代单克隆抗体具有降低的免疫原性和改善的靶向能力。单克隆抗体治疗的早期模型主要集中在增强针对肿瘤细胞的细胞溶解机制。最近，基于单克隆抗体的成功疗法针对的是参与癌细胞生长调节的分子。这突出了理解受体介导的信号转导事件的相关性，并可能为抗肿瘤抗体靶向提供新的机会。尽管存在所有这些困难，但临床数据表明抗体介导的癌症治疗作为癌症治疗中一种多功能且强大的工具，其作用日益显著。一个合理的期望是，在疾病过程的早期阶段或微小残留病阶段进行治疗可能更具优势。
